Related references
Note: Only part of the references are listed.Exploiting active nuclear import for efficient delivery of Auger electron emitters into the cell nucleus
Andrey A. Rosenkranz et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2023)
Potent candidates for Targeted Auger Therapy: Production and radiochemical considerations
Dmitry Filosofov et al.
NUCLEAR MEDICINE AND BIOLOGY (2021)
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Targeted Delivery of 111In Into the Nuclei of EGFR Overexpressing Cells via Modular Nanotransporters With Anti-EGFR Affibody
Tatiana S. Karyagina et al.
FRONTIERS IN PHARMACOLOGY (2020)
Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy
Riad Ladjohounlou et al.
CLINICAL CANCER RESEARCH (2019)
A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals
Sai Kiran Sharma et al.
NUCLEAR MEDICINE AND BIOLOGY (2019)
NLS-Cholic Acid Conjugation to IL-5R alpha-Specific Antibody Improves Cellular Accumulation and In Vivo Tumor-Targeting Properties in a Bladder Cancer Model
Michel Paquette et al.
BIOCONJUGATE CHEMISTRY (2018)
Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression
Andrey A. Rosenkranz et al.
FRONTIERS IN PHARMACOLOGY (2018)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells
Pauline Estupina et al.
ONCOTARGET (2017)
Localized Irradiation of Cell Membrane by Auger Electrons Is Cytotoxic Through Oxidative Stress-Mediated Nontargeted Effects
Salome Paillas et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
A stochastic cascade model for Auger-electron emitting radionuclides
Boon Q. Lee et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2016)
ChAcNLS, a Novel Modification to Antibody-Conjugates Permitting Target Cell-Specific Endosomal Escape, Localization to the Nucleus, and Enhanced Total Intracellular Accumulation
Simon Beaudoin et al.
MOLECULAR PHARMACEUTICS (2016)
The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells
Diana Spiegelberg et al.
ONCOTARGET (2015)
DNA damage-centered signaling pathways are effectively activated during low dose-rate Auger radioimmunotherapy
Berengere Piron et al.
NUCLEAR MEDICINE AND BIOLOGY (2014)
Apoptosis and p53 are not involved in the anti-tumor efficacy of 125I-labeled monoclonal antibodies targeting the cell membrane
Salome Paillas et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
What is the role of the Bystander response in radionuclide therapies?
Darren Brady et al.
FRONTIERS IN ONCOLOGY (2013)
A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme Clinical article
Linna Li et al.
JOURNAL OF NEUROSURGERY (2010)
Antitumor Effects and Normal-Tissue Toxicity of 111In-Nuclear Localization Sequence-Trastuzumab in Athymic Mice Bearing HER-Positive Human Breast Cancer Xenografts
Danny L. Costantini et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Noninternalizing Monoclonal Antibodies Are Suitable Candidates for 125I Radioimmunotherapy of Small-Volume Peritoneal Carcinomatosis
Lore Santoro et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences
Veerle Kersemans et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons
Jean-Pierre Pouget et al.
RADIATION RESEARCH (2008)
111In-labeled trastuzumab (herceptin) modified with nuclear localization sequences (NLS):: An Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer
Danny L. Costantini et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Cellular penetration and nuclear importation properties of In-111-labeled and I-123-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells
Bart Cornelissen et al.
NUCLEAR MEDICINE AND BIOLOGY (2007)
Radioimmunotherapy as a novel treatment regimen:: 125I-labeled monoclonal antibody 425 in the treatment of high-grade brain gliomas
TS Quang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2004)
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
LB Anthony et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2′-deoxyuridine (IdUrd)
E Galanis et al.
ANNALS OF ONCOLOGY (2001)
DNA damage induced in cells by γ and UVA radiation as measured by HPLC/GC-MS and HPLC-EC and comet assay
JP Pouget et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2000)
Share Paper
